ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31

ACADIA PHARMACEUTICALS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$19.80+0.68 (+3.56%)

Close on Oct 19, 2026

Market cap: $3.42B
P/E (TTM): 9.0
Dividend yield: –

ACADIA PHARMACEUTICALS INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	1,072	958	726	517	484	442	339	224	125	17	0.06	0.12	1.15	4.91	2.07	42	6.40
Cost of Revenue	89	82	42	10	19	10	11	12	9.08	3.08	–	–	–	–	–	–	–
Gross Profit	983	876	685	507	473	432	328	211	116	14	–	–	–	–	–	–	–
Research & Development	329	303	352	362	239	319	240	187	149	99	74	61	27	19	17	21	42
Selling, General & Admin	549	488	407	369	396	389	326	266	255	186	88	33	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	88	33	13	7.00	7.61	6.46	10
Advertising Expenses	32	21	9.40	5.50	42	51	38	40	16	1.60	–	–	–	–	–	–	–
Operating Expenses	–	–	–	–	–	–	–	–	–	–	165	93	39	26	25	27	52
Total Costs & Expenses	967	727	800	741	655	728	586	471	417	290	165	93	–	–	–	–	–
Operating Income	105	231	-73	-224	-170	-287	-247	-247	-292	-273	-165	-93	-38	-21	-23	15	-45
Income from Equity Investments	139	258	-51	-213	-168	-281	-234	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	2.37	1.82	5.11	3.54	2.33	-1.00	1.00	-1.84	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	0	0	5.11	3.54	2.33	-1.00	1.00	-1.84	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	0	0	-0.28	0.00	-0.09	0.00	-0.01	–	–	0.01	0.25	–	0.09	–
Pretax Income	139	258	-51	-213	-168	-281	-234	-244	-288	-270	-164	-92	-38	–	–	–	–
Income Tax Expense	-252	32	10	2.53	0.35	0.61	0.88	1.26	1.12	1.34	0.33	0	0	0	0.02	0.01	–
Net Income incl. Noncontrolling Interests	391	226	-61	-216	-168	-282	-235	-245	-289	-271	–	–	–	–	–	–	–
Net Income	391	226	-61	-216	-168	-282	-235	-245	-289	-271	-164	-92	-38	-21	-23	15	-45
Net Income to Common	391	226	-61	-216	–	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	2.32	1.37	-0.37	-1.34	-1.05	-1.79	-1.60	-1.94	-2.36	-2.34	-1.63	-0.95	-0.44	-0.38	-0.44	0.39	-1.20
EPS (Diluted)(per share)	2.30	1.36	-0.37	-1.34	-1.05	-1.79	-1.60	-1.94	-2.36	-2.34	-1.63	-0.95	-0.44	-0.38	-0.44	0.39	-1.20
Shares Outstanding (Basic, Weighted)(shares)	168	166	164	162	0.16	0.16	147	127	123	116	101	97	86	55	52	39	37
Shares Outstanding (Diluted, Weighted)(shares)	170	166	164	162	0.16	0.16	147	127	123	116	101	97	86	55	52	39	37
EBITDA	–	–	–	–	–	–	–	–	–	–	–	-93	-38	-21	-23	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 91.1%
Operating margin: 7.6%
Net margin: 33.4%
Return on equity, FY2025: 39.9%

Financial strength

Current ratio: 3.39
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 106.5%

Valuation

P/E ratio: 9.0
Price to sales: 3.01
Price to book: 2.62
Dividend yield: –